Dalton Einhorn is an independent consultant leveraging 30 years of experience in biotechnology and pharmaceutical product development, launch and business development, and roles in venture capital and investment banking.
He has a 360-degree background from the selection of a disease for a new molecule through development, approval, successful launch and competitive positioning and reimbursement, as well as financing and partnering.
He has the ability to create Target Product Profiles for any molecule at any stage, and map differentiation vs. competitors for strategic positioning. He has interviewed thousands of health care decision-makers in his career and can run primary and secondary market research from end to end.
As a former venture capitalist, he has a unique perspective on choosing initial indications and developing lifecycle plans that can be implemented by pharma partners, and funding and partnering. Dalton has experience in over 30 diseases, most recently, renal, immunology, rare diseases and hematology.
Veritux independent consultants are available where you need them – in all major markets and every global region.
